HLS Therapeutics Inc (OTCPK:HLTRF)

$ 2.4 0 (0%) Market Cap: 82.01 Mil Enterprise Value: 129.57 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 62/100

Q3 2024 HLS Therapeutics Inc Earnings Call Transcript
Nov 07, 2024

$2.54 (+1.60%)

Earnings
Q2 2024 HLS Therapeutics Inc Earnings Call Transcript
Aug 08, 2024

$2.22

Earnings
Q4 2023 HLS Therapeutics Inc Earnings Call Transcript
Mar 14, 2024

$3.11

Earnings
Q3 2023 HLS Therapeutics Inc Earnings Call Transcript
Nov 09, 2023

$3.75

Earnings
Q2 2023 HLS Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

$4.55

Earnings
HLS Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 16, 2023
Q1 2023 HLS Therapeutics Inc Earnings Call Transcript
May 11, 2023

$3.43 (-13.31%)

Earnings
HLS Therapeutics Inc at Bloom Burton & Co Healthcare Investor Conference Transcript
Apr 25, 2023
Q4 2022 HLS Therapeutics Inc Earnings Call Transcript
Mar 16, 2023

$5.31 (-15.85%)

Earnings
Q3 2022 HLS Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$6.97 (-0.85%)

Earnings
Q2 2022 HLS Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

$10

Earnings
HLS Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 17, 2022
Q1 2022 HLS Therapeutics Inc Earnings Call Transcript
May 05, 2022

$10.58 (-3.47%)

Earnings
HLS Therapeutics Inc at Bloom Burton & Co. Healthcare Investor Conference Transcript
May 02, 2022
HLS Therapeutics Inc Completes Negotiations with pCPA for Vascepa - Corporate Call Transcript
Apr 26, 2022
Q4 2021 HLS Therapeutics Inc Earnings Call Transcript
Mar 17, 2022

$11.73

Earnings
Q3 2021 HLS Therapeutics Inc Earnings Call Transcript
Nov 04, 2021

$15.25 (-0.39%)

Earnings
Q2 2021 HLS Therapeutics Inc Earnings Call Transcript
Aug 05, 2021

$13.99

Earnings
HLS Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 23, 2021
Q1 2021 HLS Therapeutics Inc Earnings Call Transcript
May 06, 2021

$15

Earnings
Q4 2020 HLS Therapeutics Inc Earnings Call Transcript
Mar 18, 2021

$16.2

Earnings
HLS Therapeutics Inc at Stifel Virtual Healthcare Conference Transcript
Nov 17, 2020
Q3 2020 HLS Therapeutics Inc Earnings Call Transcript
Nov 05, 2020

$12.35 (+6.54%)

Earnings
Q2 2020 HLS Therapeutics Inc Earnings Call Transcript
Aug 06, 2020

$13.27

Earnings
HLS Therapeutics Inc. - Special Call Transcript
Jul 20, 2020
HLS Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 19, 2020
HLS Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 03, 2020
Q1 2020 HLS Therapeutics Inc Earnings Call Transcript
May 07, 2020

$13.27

Earnings
Q4 2019 HLS Therapeutics Inc Earnings Call Transcript
Mar 19, 2020

$16.2

Earnings
Q3 2019 HLS Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

$11.41 (-0.26%)

Earnings
Q2 2019 HLS Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

$13.5

Earnings
Q1 2019 HLS Therapeutics Inc Earnings Call Transcript
May 09, 2019

$12.88 (+4.55%)

Earnings
Q4 2018 HLS Therapeutics Inc Earnings Call Transcript
Mar 21, 2019

$11.5 (+0.97%)

Earnings

HLS Therapeutics Inc Completes Negotiations with pCPA for Vascepa - Corporate Call Transcript

Apr 26, 2022 / 12:30PM GMT

Release Date Price: $11.49

Transcript

Operator

Good morning and welcome to today's Corporate Update Conference Call with HLS Therapeutics.

On this morning's call, we have Gilbert Godin, Chief Executive Officer; and Tim Hendrickson, Chief Financial Officer.

(Operator Instructions)

Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward-looking statements. Actual results could differ materially from those anticipated. Risk factors that could affect results are detailed in the company's annual information form which has been filed on SEDAR at www.sedar.com. During this conference call, HLS will refer to adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS. Adjusted EBITDA is defined in the company's press release and annual filings that are available on SEDAR and on the company's website.

Please note that all financial information provided is in Canadian dollars unless otherwise specified.

I would now like to turn the meeting over to Mr. Godin.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.